FOR IMMEDIATE RELEASE: May 07, 2013
Christine Frey, AUA
STENT IMPLANTATION A VIABLE OPTION FOR THE TREATMENT OF ERECTILE DYSFUNCTION
Review of One Year Trial Results
San Diego, CA, May 7, 2013- Stenting a pelvic artery is safe and appears to be a promising treatment option for erectile dysfunction (ED) in men who do not respond to drug therapy, according to a new study at the 108th Annual Scientific Meeting of the American Urological Association (AUA). The study will be presented to reporters during a special press conference at the San Diego Convention Center, San Diego, CA on Tuesday, May 7 at 10:30 a.m. PDT. Ira D. Sharlip, MD, AUA Spokesperson and Professor of Urology, University of California, San Francisco, CA will moderate the session for media.
An estimated 30 million men in the United States and more than 300 million worldwide suffer from ED. The majority of cases stem from vascular problems, including insufficient blood flow from the arteries, and is why researchershave suggested stenting pelvic arteries such as the internal pudendal arteries (IPA) can improve ED and sexual function.
To assess the safety, practicality and outcomes of stent implantation in IPAs among men with ED, researchers from several leading institutions within the United States, including San Diego Sexual Medicine, Prairie Heart Institute, UC Davis, and Southern Illinois University School of Medicine, conducted a prospective, multi-center, single-arm, safety and feasibility trial. The study enrolled 30 patients with established ED, confirmed obstructive atherosclerosis and little to no responseto PDE5 inhibitors (oral medications). The primary safety endpoint was any major adverse event 30 days after the procedure, and the primary feasibility endpoint was improvement in the International Index of Erectile Function (IIEF) score of at least four points at the three month interval.
Overall, a total of 45 lesions were treated with stents. The primary safety endpoint at 30 days was met in all subjects and there were no subsequent safety events during the 12 months of follow-up. In the intention-to-treat analysis, the primary feasibility endpoint results indicate 81 percent of patients who received a stent had an improvement of at least four points on the IIEF scale at the one-year mark, compared to 59.3 percent at the three and six month intervals. Additionally, mean peak systolic velocity nearly doubled from 16.4 cm/sec at baseline to 32.4 cm/sec at one year.
"While the results of the study are promising and provide several insights into endovascular intervention and the treatment of ED, there are many causes for erectile dysfunction,” said Dr. Sharlip. “I would not want anyone to think a stent alone is the answer to all cases of ED.”
NOTE TO REPORTERS: Experts are available to discuss this study outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number above or e-mail Communications@AUAnet.org.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 19,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.